相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Poly(ADP-ribose) polymerase 1 regulates mitochondrial DNA repair in an NAD-dependent manner
Geoffrey K. Herrmann et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells
Abdelnour H. Alhourani et al.
SCIENTIFIC REPORTS (2021)
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination
Shereen El Shorbagy et al.
JOURNAL OF GASTROINTESTINAL CANCER (2021)
Metformin: current clinical applications in nondiabetic patients with cancer
Kailin Chen et al.
AGING-US (2020)
Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Davide Angeli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion
Megan Randall et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Alvaro Lahiguera et al.
EMBO MOLECULAR MEDICINE (2020)
Biguanides in combination with olaparib limits tumorigenesis of drug-resistant ovarian cancer cells through inhibition of Snail
Qiong Wang et al.
CANCER MEDICINE (2020)
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
Elaine Sanij et al.
NATURE COMMUNICATIONS (2020)
Chemical modification of melphalan as a key to improving treatment of haematological malignancies
Arkadiusz Gajek et al.
SCIENTIFIC REPORTS (2020)
Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
Marianna Buttarelli et al.
CANCERS (2020)
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Daniel Martin Klotz et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2020)
FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination
Elaine Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
Jorgen Smeby et al.
EBIOMEDICINE (2020)
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
Patrycja Gralewska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Metformin: Metabolic Rewiring Faces Tumor Heterogeneity
Mario Cioce et al.
CELLS (2020)
Metformin partially reverses the inhibitory effect of co-culture with ER-/PR-/HER2+ breast cancer cells on biomarkers of monocyte antitumor activity
Zoheir Dahmani et al.
PLOS ONE (2020)
PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers
Geraldine Gentric et al.
CELL METABOLISM (2019)
Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways
Liwei Ma et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets
Kristen E. Mengwasser et al.
MOLECULAR CELL (2019)
Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells
Aneta Rogalska et al.
PHYTOMEDICINE (2019)
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
Rachel M. Hurley et al.
GYNECOLOGIC ONCOLOGY (2019)
PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells
Anna Maria Cseh et al.
FRONTIERS IN PHYSIOLOGY (2019)
Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The Opt-Out Process
Jacob McGee et al.
JOURNAL OF ONCOLOGY (2019)
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage
Sara Giovannini et al.
NUCLEIC ACIDS RESEARCH (2019)
Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1
Tahira Baloch et al.
BMC CANCER (2019)
The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer
Mette Hjortkjaer et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
Irem Durmaz Sahin et al.
Oncotarget (2019)
Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery
I. Nyoman Gede Budiana et al.
JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION (2019)
Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer
Zehua Wang et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2019)
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?
Benedetta Pellegrino et al.
ESMO OPEN (2019)
PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
Leslie A. Parsels et al.
MOLECULAR CANCER RESEARCH (2018)
Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells
Yi Zhao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
Belinda van Zyl et al.
ENDOCRINE-RELATED CANCER (2018)
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
Andrew J. Wilson et al.
GYNECOLOGIC ONCOLOGY (2018)
Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation
Guiju Tang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
George E. Ronson et al.
NATURE COMMUNICATIONS (2018)
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer
Dong Hou et al.
REDOX BIOLOGY (2018)
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
Xiangbing Meng et al.
CANCERS (2018)
Novel oxazolinoanthracyclines as tumor cell growth inhibitors-Contribution of autophagy and apoptosis in solid tumor cells death
Aneta Rogalska et al.
PLOS ONE (2018)
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
Z. Ping Lin et al.
PLOS ONE (2018)
Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment
Abdul Khalid Siraj et al.
Oncotarget (2018)
Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells
Nipun Saini et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2018)
TP53 Mutations in Breast and Ovarian Cancer
Laxmi Silwal-Pandit et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells
Benigno C. Valdez et al.
LEUKEMIA & LYMPHOMA (2017)
Autophagy and Protein Kinase RNA-Like Endoplasmic Reticulum Kinase (PERK)/Eukaryotic Initiation Factor 2 Alpha Kinase (eIF2α) Pathway Protect Ovarian Cancer Cells From Metformin-Induced Apoptosis
Hee-sun Moon et al.
MOLECULAR CARCINOGENESIS (2016)
The enhancement of oxidative DNA damage by anti-diabetic metformin, buformin, and phenformin, via nitrogen-centered radicals
Shiho Ohnishi et al.
FREE RADICAL RESEARCH (2016)
Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding
Eun Young Park et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Metformin: An anti-diabetic drug to fight cancer
Marie Daugan et al.
PHARMACOLOGICAL RESEARCH (2016)
Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53
Mahsa Alaee et al.
PLOS ONE (2016)
Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation
Idun Dale Rein et al.
CELL CYCLE (2015)
Synthetic lethality of PARP inhibitors and metformin in BRCA1 intact ovarian cancer
M. Hijaz et al.
GYNECOLOGIC ONCOLOGY (2015)
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells
Caroline V. M. Verhagen et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Metformin and epithelial ovarian cancer therapeutics
Seema Patel et al.
CELLULAR ONCOLOGY (2015)
The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells
Stefania Orecchioni et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma
Carmela Passaro et al.
MOLECULAR ONCOLOGY (2015)
Oxidative stress-induced p53 activity is enhanced by a redox-sensitive TP53INP1 SUMOylation
S. Peuget et al.
CELL DEATH AND DIFFERENTIATION (2014)
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Corine M. Beaufort et al.
PLOS ONE (2014)
Epothilone B induces extrinsic pathway of apoptosis in human SKOV-3 ovarian cancer cells
Aneta Rogalska et al.
TOXICOLOGY IN VITRO (2014)
Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B
Aneta Rogalska et al.
TOXICOLOGY IN VITRO (2013)
Tumour-associated mutant p53 drives the Warburg effect
Cen Zhang et al.
NATURE COMMUNICATIONS (2013)
Evaluating cell lines as tumour models by comparison of genomic profiles
Silvia Domcke et al.
NATURE COMMUNICATIONS (2013)
Surf the Post-translational Modification Network of p53 Regulation
Bo Gu et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures
Daniel K. Chan et al.
JOURNAL OF OVARIAN RESEARCH (2012)
PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation
Peter Bai et al.
CELL METABOLISM (2011)
Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1
Sharon B. Cantor et al.
FUTURE ONCOLOGY (2011)
The role of mutant p53 in human cancer
Amanda M. Goh et al.
JOURNAL OF PATHOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities
Gregory T. Langland et al.
ONCOLOGY REPORTS (2010)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
Ovarian cancer: pathology, biology, and disease models
Daniel G. Rosen et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Transcription-independent pro-apoptotic functions of p53
UM Moll et al.
CURRENT OPINION IN CELL BIOLOGY (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
分享论文
